Abstract 381P
Background
The most frequent and aggressive primary brain malignancy in adults is a glioblastoma multiforme (GBM) which is frequently resistant to apoptosis-inducing chemotherapeutic agents. Surface exposure of phosphatidylserine (PS) is a universally recognized apoptotic phenomenon. Although in acute myeloid leukemia and T-cell lymphoma cells Xkr8 mediates PS exposure in response to apoptotic stimuli, the mechanisms underlying the regulation of Xkr8 expression remain unclear. Nevertheless, the loss of Xkr8 in blood cancer cells blocks cell-surface exposure of PS and causes dramatic decreasing of engulfment by phagocytes. Whether Xkr8 is dysregulated in specific cancers and contribute to the survival of patients has not been investigated. This study was aimed to investigate the association of overall survival (OS) and disease-free survival (DFS) with expression and copy number alterations (CNA) of XKR8 gene in GBM patients.
Methods
Data of gene expression, CNA and clinical information from 619 GBM tumors were obtained from TCGA Glioblastoma Multiforme study using the open platform CBioPortal. Among all cases, 572 GBM samples were with CNA (GISTIC 2.0. Values) data and 162 samples were with mRNA expression data (RNA Seq V2 RSEM). Patients were divided into two groups taking into account CNA or expression of mRNA. XKR8 expression was scored as downregulated when mRNA value was lower than the mean expression + standard deviation. XKR8 gene was marked as amplified when CNA value was equal 1 or 2. Kaplan-Meier and log-rank analyses were performed using RStudio.
Results
Survival analysis in GBM patients showed that the OS (p-value=0,015) of the group with downregulated XKR8 mRNA expression (n = 22) was better than of group with normal and upregulated expression (n = 140). Equivalent results have been shown for DFS, where the patients with low XKR8 expression (n = 15) had a weaker risk of disease recurrence (p-value=0,003) than other GBM patients (n = 103). Also, the OS of GBM patients with amplified XKR8 gene (n = 83) was worse (p-value=0,049) than of patients with other CNAs (n = 489).
Conclusions
Thus XKR8 gene can be characterized as prognostic biomarker of survival and disease progression in GBM patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Research Laboratory "Biomarker" IFMB KFU.
Funding
Russian Government Program of Competitive Growth of Kazan Federal University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract